Journal Mobile Options
Table of Contents
Vol. 38, No. 3, 2006
Issue release date: May 2006
Ophthalmic Res 2006;38:149–157

Effect of Berberine on Interleukin 8 and Monocyte Chemotactic Protein 1 Expression in a Human Retinal Pigment Epithelial Cell Line

Cui H.-S. · Hayasaka S. · Zhang X.-Y. · Hayasaka Y. · Chi Z.-L. · Zheng L.-S.
Departments of aOphthalmology and bPathology, Toyama Medical and Pharmaceutical University, Toyama, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Purpose: The aims of this study were to examine the effects of berberine, an alkaloid isolated from some medicinal herbs, on interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) expression in a human retinal pigment epithelial cell line (ARPE-19) stimulated with interleukin 1β (IL-1β) or tumor necrosis factor α (TNF-α). Methods: ARPE-19 cells were cultured to confluence. Berberine and IL-1β or TNF-α were added to the medium. IL-8 mRNA and MCP-1 mRNA were measured by semiquantitative reverse-transcription polymerase chain reaction and real-time polymerase chain reaction. IL-8 and MCP-1 protein concentrations in the media were measured using enzyme-linked immunosorbent assay. Results: Berberine dose-dependently inhibited IL-8 mRNA and MCP-1 mRNA expression of the cells and protein levels in the media stimulated with IL-1β or TNF-α. Conclusion: These findings indicate that berberine dose-dependently inhibited the expression of IL-8 and MCP-1 induced by IL-1β or TNF-α.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Elner VM, Strieter RM, Elner SG, Baggiolini M, Lindley I, Kunkel SL: Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 1990;136:745–750.
  2. Elner SG, Strieter R, Elner VM, Rollins BJ, Del Monte MA, Kunkel SL: Monocyte chemotactic protein gene expression by cytokine-treated human retinal pigment epithelial cells. Lab Invest 1991;64:819–825.
  3. Crane IJ, Wallace CA, Mckillop-Smith S, Forrester JV: Control of chemokine production at the blood-retina barrier. Immunology 2000;101:426–433.
  4. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM: ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996;62:155–169.
  5. Nakamura N, Hayasaka S, Zhang XY, Nagaki Y, Matsumoto M, Hayasaka Y, Terasawa K: Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor κB binding activities induced by interleukin-1β in human retinal pigment epithelial cell line. Exp Eye Res 2003;77:195–202.
  6. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.
  7. Claudio L, Martiney JA, Brosnan CF: Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1β or tumor necrosis factor-α. Lab Invest 1994;70:850–861.
  8. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM: Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053.
  9. Aksunger A, Or M, Okur H, Hasanreisoglu B, Akbatur H: Role of interleukin 8 in the pathogenesis of proliferative vitreoretinopathy. Ophthalmologica 1997;211:223–225.
  10. Abu El-Asrar AM, Van Damme JO, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L: Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997;123:599–606.
  11. Capeans C, De Rojas MV, Lojo S, Salorio MS: C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546–550.
  12. Elner SG, Strieter R, Bian ZM, Kunkel S, Mokhtarzaden L, Johnson M, Lukacs N, Elner VM: Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998;116:1597–1601.
  13. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S: Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complic 2001;15:257–259.
  14. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J: Monocyte chemotactic protein-1 in patients with proliferative diabetic retinopathy. Ophthalmologica 2001;215:415–418.
  15. Cicik E, Tekin H, Akar S, Ekmekci OB, Donma O, Koldas L, Ozkan S: Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res 2003;35:251–255.
  16. Nicoletti R, Venza I, Ceci G, Visalli M, Teti D, Reibaldi A: Vitreous polyamines spermidine, putrescine, and spermine in human proliferative disorders of the retina. Br J Ophthalmol 2003;87:1038–1042.
  17. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H: Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J Ethnopharmacol 1999;66:227–233.
  18. Zhou H, Mineshita S: The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther 2000;294:822–829.
  19. Kupeli E, Kosar M, Yesilada E, Baser KH, Baser C: A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci 2002;72:645–657.
  20. Lee DU, Kang YJ, Park MK, Lee YS, Seo HG, Kim TS, Kim CH, Chang KC: Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-α, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci 2003;73:1401–1412.
  21. Kuo CL, Chi CW, Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004;203:127–137.
  22. Luo LJ: Experience of berberine in the treatment of diarrhea. Chin J Med 1955;41:452–455.
  23. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J: Effects of berberine on glucose metabolism in vitro. Metabolism 2002;51:1439–1443.
  24. Leng SH, Lu FE, Xu LJ: Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004;25:496–502.
  25. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD: Berberine is a noval cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344–1351.
  26. Abe T, Sugano E, Saigo Y, Tamai M: Interleukin-1β and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci 2003;44:4097–4104.
  27. Cui HS, Hayasaka S, Zhang XY, Hayasaka Y, Chi ZL: Effects of α-melanocyte-stimulating hormone on interleukin-8 and monocyte chemotactic protein-1 expression in human retinal pigment epithelial cell line. Ophthalmic Res 2005;37:279–288.
  28. Shen MP, Sun Q, Wang H: Studies on the intravenous pharmacokinetics and oral absorption of berberine HCL in beagle dogs. Chin Pharmacol Bull 1993;9:64–67.
  29. Li BX, Zhang MS, Bao LH: Study on the pharmacokinetics of berberine after oral administration in human being. Harbin Med Univ Bull 1995;29:382–385.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50